Modelling population-level impact to inform target product profiles for childhood malaria vaccines

[1]  Hannah C. Slater,et al.  The US President's Malaria Initiative, Plasmodium falciparum transmission and mortality: A modelling study , 2017, PLoS medicine.

[2]  A. Wallqvist,et al.  Delayed fractional dose regimen of the RTS,S/AS01 malaria vaccine candidate enhances an IgG4 response that inhibits serum opsonophagocytosis , 2017, Scientific Reports.

[3]  C. Elias,et al.  Reaching everyone, everywhere with life-saving vaccines , 2017, The Lancet.

[4]  N. Waters,et al.  Fractional Third and Fourth Dose of RTS,S/AS01 Malaria Candidate Vaccine: A Phase 2a Controlled Human Malaria Parasite Infection and Immunogenicity Study. , 2016, The Journal of infectious diseases.

[5]  P. Walker,et al.  Estimating the most efficient allocation of interventions to achieve reductions in Plasmodium falciparum malaria burden and transmission in Africa: a modelling study. , 2016, The Lancet. Global health.

[6]  Katya Galactionova,et al.  Public health impact and cost-effectiveness of the RTS,S/AS01 malaria vaccine: a systematic comparison of predictions from four mathematical models , 2016, The Lancet.

[7]  Kwaku Poku Asante,et al.  Immunogenicity of the RTS,S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial , 2015 .

[8]  S. C. T. P. Rts.  Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial , 2015, The Lancet.

[9]  Peter G. Kremsner,et al.  Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. , 2015 .

[10]  A. Ghani,et al.  Gradual acquisition of immunity to severe malaria with increasing exposure , 2015, Proceedings of the Royal Society B: Biological Sciences.

[11]  Neil M. Ferguson,et al.  Estimates of the changing age-burden of Plasmodium falciparum malaria disease in sub-Saharan Africa , 2014, Nature Communications.

[12]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[13]  J. Simpson,et al.  Implications of the licensure of a partially efficacious malaria vaccine on evaluating second-generation vaccines , 2013, BMC Medicine.

[14]  T. Hoffmann,et al.  Cost effectiveness of patient education for the prevention of falls in hospital: economic evaluation from a randomized controlled trial , 2013, BMC Medicine.

[15]  Kwaku Poku Asante,et al.  Safety and efficacy of the RTS,S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial. , 2011, The Lancet. Infectious diseases.

[16]  Thomas Smith,et al.  A Research Agenda for Malaria Eradication: Modeling , 2011, PLoS medicine.

[17]  Wes Hinsley,et al.  Reducing Plasmodium falciparum Malaria Transmission in Africa: A Model-Based Evaluation of Intervention Strategies , 2010, PLoS medicine.

[18]  W. Ballou.  The development of the RTS,S malaria vaccine candidate: challenges and lessons , 2009, Parasite immunology.

[19]  A. Ghani,et al.  Loss of Population Levels of Immunity to Malaria as a Result of Exposure-Reducing Interventions: Consequences for Interpretation of Disease Trends , 2009, PloS one.

[20]  H Peltola,et al.  Vaccination greatly reduces disease, disability, death and inequity worldwide. , 2008, Bulletin of the World Health Organization.